“Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project”, Reumatismo, vol. 61, no. 1, pp. 54–64, Mar. 2009, doi: 10.4081/reumatismo.2009.54.